PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...

Shares of PTC Inc. (NASDAQ:PTC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Four ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00 ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price rose 4.8% on Tuesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00. Robert W. Baird currently ...

However, on the same day, Robert W. Baird maintained a Buy rating on PTC Therapeutics (NASDAQ: PTCT). The company has a one-year high of $46.98 and a one-year low of $20.75. Currently, PTC ...

In a report released today, Joseph Thome from TD Cowen maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price ...

PTC Therapeutics (PTCT) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150M ...

PTC Therapeutics ( (PTCT) ) just unveiled an update.

Baird analyst Joel Beatty raised the firm’s price target on PTC Therapeutics (PTCT) to $52 from $48 and keeps an Outperform rating on the ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the ...

PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...